deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT04068181

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy

Sponsor: Amgen

Conditions Melanoma
Interventions Pembrolizumab Talimogene laherparepvec
Updated 26 times since 2019 Last updated: Dec 12, 2024 Started: Jan 22, 2020 Primary completion: Aug 19, 2021 Completion: Feb 26, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Melanoma, this trial is completed. The trial is conducted by Amgen and has accumulated 26 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2023 · 14 months · monthly snapshot~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

26 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 21 earlier versions

  1. Nov 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2022 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Sep 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Mar 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  10. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  11. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  12. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  13. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  14. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  15. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  16. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  17. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  18. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  19. Nov 2019 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE2

  20. Oct 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE2

  21. Sep 2019 — Oct 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
  • Merck Sharp & Dohme LLC
Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Amsterdam, Netherlands , Athens, Greece , Austin, United States , Barcelona, Spain , Bergamo, Italy , Bordeaux, France , Cleveland, United States , Dallas, United States , Donostia / San Sebastian, Spain and 33 more locations